Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
Solène M. Evrard,
Sarah Péricart,
David Grand,
Nadia Amara,
Frédéric Escudié,
Julia Gilhodes,
Pierre Bories,
Alexandra Traverse-Glehen,
Romain Dubois,
Pierre Brousset,
Marie Parrens,
Camille Laurent
Affiliations
Solène M. Evrard
Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole;Toulouse III Paul Sabatier University;Inserm, UMR1037 Centre de Recherche en Cancerologie de Toulouse, laboratoire d’excellence TOUCAN
Sarah Péricart
Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole
David Grand
Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole
Nadia Amara
Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole
Frédéric Escudié
Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole
Julia Gilhodes
Department of Biostatistics, IUCT-Oncopole, CHU Toulouse
Pierre Bories
Regional Cancer Network Onco-occitanie, IUCT-Oncopole, Toulouse
Alexandra Traverse-Glehen
Hospices Civils de Lyon, Claude Bernard Lyon 1 University, INSERM 1052, Pierre-Bénite
Romain Dubois
Institut de Pathologie, CHU Lille, Avenue Oscar Lambret
Pierre Brousset
Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole;Toulouse III Paul Sabatier University;Inserm, UMR1037 Centre de Recherche en Cancerologie de Toulouse, laboratoire d’excellence TOUCAN
Marie Parrens
Pathology, CHU Bordeaux, Inserm U1053, France
Camille Laurent
Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole;Toulouse III Paul Sabatier University;Inserm, UMR1037 Centre de Recherche en Cancerologie de Toulouse, laboratoire d’excellence TOUCAN
